Evaluate the Efficacy and Safety of Multiple Roxadustat Dosing Regimens for the Treatment of Anemia in Dialysis Participants With Chronic Kidney Disease
A Prospective, Randomized, Open-Label, Multi-Center Study to Evaluate the Efficacy and Safety of Multiple Roxadustat Dosing Regimens for the Treatment of Anemia in Dialysis Subjects With Chronic Kidney Disease
This is a randomized, open-label, multi-center study in dialysis chronic kidney disease (CKD) participants to evaluate the efficacy and relative safety of different dosing regimens of roxadustat over a 36-week treatment period.
There are 3 study periods:
- Screening Period (up to 4 weeks)
- Treatment Period (36 weeks)
Part 1: Correction/Conversion Period (Weeks 1-20)
Part 2: Hemoglobin (Hb) Maintenance Period (Weeks 21-36)
- Follow-up Period (4 weeks)
研究概览
详细说明
Approximately 102 erythropoiesis stimulating agents (ESA)-naïve participants and 204 ESA-treated participants will be enrolled and randomized respectively in a 1:1 ratio to receive roxadustat at one of 2 starting doses as below:
- Low weight-based dosing: 70 milligrams (mg) 3 times a week (TIW) for body weight <60 kilograms (kg) or 100 mg TIW for body weight ≥60 kg
- Standard weight-based dosing: 100 mg TIW for body weight <60 kg or 120 mg TIW for body weight ≥60 kg
After 20 weeks of treatment, all eligible participants whose last 2 Hb levels ≥105 grams (g)/liter (L) and change in Hb over the most recent 4 weeks is > - 10 g/L will switch to receive roxadustat for another 16 weeks to evaluate the efficacy and safety of new dosing regimens.
At the end of Week 36, all participants will discontinue roxadustat and enter a 4-week Follow-up Period.
研究类型
注册 (实际的)
阶段
- 第四阶段
联系人和位置
学习地点
-
-
-
Beijing、中国、100044
- Investigational site
-
Beijing、中国、100191
- Investigational site
-
Beijing、中国、100730
- Investigational site
-
Shanghai、中国、200025
- Investigational site
-
Tianjin、中国、300052
- Investigational site
-
-
Anhui
-
Hefei、Anhui、中国、230601
- Investigational site
-
-
Gansu
-
Lanzhou、Gansu、中国、730030
- Investigational site
-
-
Guangdong
-
Guangzhou、Guangdong、中国、510515
- Investigational site
-
Shenzhen、Guangdong、中国、518020
- Investigational site
-
-
Guangxi Province
-
Nanning、Guangxi Province、中国、530021
- Investigational site
-
-
Henan
-
Zhengzhou、Henan、中国、450052
- Investigational site
-
-
Hubei
-
Wuhan、Hubei、中国、430060
- Investigational site
-
-
Hunan
-
Changsha、Hunan、中国、410008
- Investigational site
-
-
Inner Mongolia Autonomous Region
-
Baotou、Inner Mongolia Autonomous Region、中国、014010
- Investigational site
-
-
Jiangsu
-
Nanjing、Jiangsu、中国、210009
- Investigational site
-
-
Jiangxi
-
Nanchang、Jiangxi、中国、330006
- Investigational site
-
-
Jilin
-
Chang chun、Jilin、中国、130021
- Investigational site
-
-
Liaoning
-
Shenyang、Liaoning、中国、110004
- Investigational site
-
Shenyang、Liaoning、中国、110122
- Investigational site
-
-
Shanxi
-
Taiyuan、Shanxi、中国、030001
- Investigational site
-
Xi'an、Shanxi、中国、710004
- Investigational site
-
Xi'an、Shanxi、中国、710061
- Investigational site
-
-
Sichuan
-
Chengdu、Sichuan、中国、610041
- Investigational site
-
Chengdu、Sichuan、中国、610072
- Investigational site
-
-
Zhejiang
-
Hangzhou、Zhejiang、中国、310003
- Investigational site
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
1. CKD with end-stage renal disease (ESRD) on either hemodialysis (HD) or peritoneal dialysis (PD)
Exclusion Criteria:
- Positive for any of the following: human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or anti-hepatitis C virus antibody (anti-HCV Ab).
- Myocardial infarction, acute coronary syndrome, stroke, seizure, or a thromboembolic event (for example, deep venous thrombosis or pulmonary embolism) within 26 weeks prior to Day 1.
- History of malignancy, myelodysplastic syndrome, and multiple myeloma.
- Chronic inflammatory disease other than glomerulonephritis that could impact erythropoiesis (for example, systemic lupus erythematosis [SLE], rheumatoid arthritis, celiac disease).
- Clinically significant gastrointestinal bleeding.
- Women of childbearing potential and men with sexual partners of child bearing potential who are not using adequate contraception.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
实验性的:Part 1: ESA-Naïve Participants - Low Weight Based Dosing
ESA-naïve participants will receive roxadustat 70 mg TIW for body weight 45 to <60 kg or 100 mg TIW for body weight ≥60 kg.
|
Roxadustat will be dosed orally per dose and schedule specified in the arm description.
其他名称:
|
实验性的:Part 1: ESA-Naïve Participants - Standard Weight Based Dosing
ESA naïve participants will receive roxadustat 100 mg TIW for body weight 45 to <60 kg or 120 mg TIW for body weight ≥60 kg.
|
Roxadustat will be dosed orally per dose and schedule specified in the arm description.
其他名称:
|
实验性的:Part 1: ESA-Treated Participants - Low Weight Based Dosing
ESA-treated participants will receive roxadustat 70 mg TIW for body weight 45 to <60 kg or 100 mg TIW for body weight ≥60 kg.
|
Roxadustat will be dosed orally per dose and schedule specified in the arm description.
其他名称:
|
实验性的:Part 1: ESA-Treated Participants - Standard Weight Based Dosing
ESA treated participants will receive roxadustat 100 mg TIW for body weight 45 to <60 kg or 120 mg TIW for body weight ≥60 kg.
|
Roxadustat will be dosed orally per dose and schedule specified in the arm description.
其他名称:
|
实验性的:Part 2: Roxadustat QW
Participants will receive roxadustat once a week (QW).
Roxadustat dose will be 2-dose step increase from originally planned week 21 TIW per dose amount.
|
Roxadustat will be dosed orally per dose and schedule specified in the arm description.
其他名称:
|
实验性的:Part 2: Roxadustat BIW
Participants will receive roxadustat twice a week (BIW).
Roxadustat dose will be 1-dose step increase from originally planned week 21 TIW per dose amount.
|
Roxadustat will be dosed orally per dose and schedule specified in the arm description.
其他名称:
|
实验性的:Part 2: Roxadustat TIW
Participants will receive roxadustat TIW.
Roxadustat dose will continue per dose adjustment guideline.
|
Roxadustat will be dosed orally per dose and schedule specified in the arm description.
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
---|---|
Part 1 (ESA Naïve): Percentage of Participants who Achieved Hb ≥110 g/L in the First 20 Weeks
大体时间:Weeks 1 to 20
|
Weeks 1 to 20
|
Part 1 (ESA Treated): Percentage of Participants who Achieved Mean Hb ≥100 g/L Averaged Over Weeks 17 to 21 Visits
大体时间:Weeks 17 to 21
|
Weeks 17 to 21
|
Part 2: Mean Hb Value Averaged Over Weeks 33 to 37 Visits
大体时间:Weeks 33 to 37
|
Weeks 33 to 37
|
次要结果测量
结果测量 |
大体时间 |
---|---|
Part 1: Mean Change in Hb Level From Baseline to Average Over Weeks 17 to 21 Visits
大体时间:Baseline, Weeks 17 to 21
|
Baseline, Weeks 17 to 21
|
Part 1 (ESA-Naïve): Percentage of Participants With Mean Hb (Averaged Weeks 17 to 21 Visits) ≥100 g/L
大体时间:Weeks 17 to 21
|
Weeks 17 to 21
|
Part 2: Percentage of Participants With Mean Hb (Averaged Weeks 33 to 37 Visits) ≥100 g/L
大体时间:Weeks 33 to 37
|
Weeks 33 to 37
|
合作者和调查者
赞助
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.